1.Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602.
2.Van Ameringen, MA, Lane, RM, Walker, JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001; 158(2): 275–281.
3.Stein, MB, Liebowitz, MR, Lydiard, RB, Pitts, CD, Bushnell, W, Gergel, I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998; 280(8): 708–713.
4.Stein, MB, al. e. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005; 177(3): 280–288.
5.Stein, MB, Pollack, MH, Bystritsky, A, Kelsey, JE, Mangano, RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005; 177(3): 280–288.
6.Liebowitz, MR, Stein, MB, Tancer, M, Carpenter, D, Oakes, R, Pitts, CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002; 63(1): 66–74.
7.Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003; 18(2): 53–61.
8.Fava, M, Martinez, JM, Greist, J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007; 19(3): 187–195.
9.Koponen, H, Allgulander, C, Erickson, J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry. 2007; 9(2): 100–107.
10.Crippa, JA, Filho, AS, Freitas, MC, Zuardi, AW. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol. 2007; 27(3): 310.
11.Lin, CC. Duloxetine treatment of social anxiety disorder with comorbid major depression. J Clin Psychopharmacol. 2008; 28(5): 591–592; author reply 592–593.
12.Scott, EL, Pollack, MH, Otto, MW, Simon, NM, Worthington, JJ. Clinician response to treatment refractory panic disorder: a survey of psychiatrists. J Nerv Ment Dis. 1999; 187(12): 755–757.
13.First, MS, Gibbon, M, Williams, JBW. Structured Clinical Interview for Axis I DSM-IV Disorders - Patient version (SCID-1/P version 2.0). New York, NY: New York State Psychiatric Institute Biometrics Research Department; 1994.
14.Doyle, AC, Pollack, MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry. 2003; 64(Suppl 15): 40–45.
15.Ballenger, JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999; 60(Suppl 22): 29–34.
16.Sheehan, DV, Harnett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11(Suppl 3): 89–95.
17.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993; 29(2): 321–326.
18.Rapaport, MH, Davidson, JR. The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. Psychopharmacol Bull. 1998; 34(2): 167–168.
19.Schneier, FR, Heckelman, LR, Garfinkel, R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994; 55(8): 322–331.
20.Davidson, JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006; 67(Suppl 12): 20–26.
21.Kornstein, SG, Dunner, DL, Meyers, AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry. 2008; 69(9): 1383–1392.
22.Cymbalta delayed-release capsules. In: Physician's Desk Reference. 63rd ed. Montvale, NJ: Thomson PDR; 2009.